Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

NCT02822066 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT02822066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02822066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
June 30, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory neoplasms